-
公开(公告)号：US20180110847A1
公开(公告)日：2018-04-26
申请号：US15789260
申请日：2017-10-20
申请人： BATU BIOLOGICS, INC.
发明人： Samuel C. Wagner , Thomas E. Ichim
CPC分类号： A61K39/0011 , A61K2039/515 , C12N5/0605 , C12N5/069 , C12N2500/00 , C12N2500/40 , C12N2500/60 , C12N2501/24
摘要： Disclosed are methods, protocols, and compositions of matter useful for treatment of cancer by elicitation of immunity towards tumor blood vessels. In one embodiment, the invention teaches the stimulation of expression of tumor blood vessel associated antigens in cells derived from endothelial progenitor cells, through culture of cells in conditions resembling the tumor microenvironment. In another embodiment, the invention teaches increasing immunogenicity of endothelial progenitor cells or progeny thereof through treatment with agents such as interferon gamma, which are capable of upregulating histocompatibility antigens, which allow for allogeneic rejection upon administration. In another embodiment, the invention teaches immunization with endothelial progenitor cells or progeny thereof treated under conditions to resemble tumor blood vessels, in which administered cells are purposely mismatched with recipient HLA in order to provide for enhanced allogenicity. In one embodiment, purposeful mismatching is accomplished through transfection or “cell painting” of molecules capable of eliciting an immunological response.
-
公开(公告)号：US20180008670A1
公开(公告)日：2018-01-11
申请号：US15712887
申请日：2017-09-22
申请人： Batu Biologics, Inc.
发明人： Samuel C. Wagner , Thomas E. Ichim , Boris Minev
IPC分类号： A61K38/17 , C07K14/705 , C07K14/725
CPC分类号： A61K38/1793 , A61K35/17 , A61K38/1774 , C07K14/7051 , C07K14/70521 , C07K14/70578 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C07K2319/70 , C07K2319/74 , A61K2300/00
摘要： Disclosed are methods, protocols, and compositions of matter related to utilization of chimeric antigen receptor (CAR) expressing cells for the targeting of tumor endothelium utilizing chimeric antigen receptor expressing stem cells. In one embodiment tumor endothelium specific antigens are utilized as targets of the antigen binding domain of a CAR, which is attached to an extracellular hinge domain, a domain that transverses the T cell membrane and an intracellular domain associated with T cell signaling. Suitable antigens for the practice of the invention include TEM-1, ROBO-4, surviving, and FasL. In other aspects of the invention antigens are identified through serological analysis of recombinant cDNA expression libraries (SEREX) using plasma from a patient immunized with placental endothelial cells.
-
公开(公告)号：US20170095545A1
公开(公告)日：2017-04-06
申请号：US15149130
申请日：2016-05-07
申请人： Batu Biologics, Inc.
CPC分类号： A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/515 , C07K16/2818 , A61K2300/00
摘要： Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors. Means of differentiating tumor cells directly into endothelial or endothelial-like cells and utilizing said cells as immunogens for the purpose of inducing immunity against blood vessels feeding tumors. In one embodiment CTLA4 blockade is performed in combination with an immunogen capable of triggering immunity towards tumor endothelial cells. In another embodiment blockade of the PD1-PD1 ligand pathway is performed in combination with induction of anti-angiogenic immune response.
-
公开(公告)号：US20160213764A1
公开(公告)日：2016-07-28
申请号：US15004864
申请日：2016-01-22
申请人： Batu Biologics, Inc.
IPC分类号： A61K39/00 , C12N5/0784 , A61K45/06
CPC分类号： A61K39/0011 , A61K45/06 , A61K2039/5152 , A61K2039/5154 , A61K2039/5156 , C12N5/0605 , C12N2502/30
摘要： Disclosed are composite cancer vaccines, in one embodiment generated through 3-dimensional bioprinting or through inoculation of roller cultures. The utilization of decellularized biological matrices such as placental tissue or subintestinal submucosal tissue is disclosed as a substrate for 3-dimensional tissue culture. In one embodiment tumor cells are assembled with monocytes and/or mesenchymal stem cells to represent in vivo existing tumors. The invention teaches means of generating off-the-shelf tumor vaccines containing antigenic properties similar to in vivo growing tumors, which cannot be currently replicated under existing 2-dimensional tumor culture means of generating cell lines
摘要翻译： 公开的是复合癌症疫苗，在一个实施方案中通过三维生物印迹或通过接种滚筒培养物产生。 公开了脱细胞生物基质如胎盘组织或小肠粘膜下组织的利用作为三维组织培养的底物。 在一个实施方案中，肿瘤细胞与单核细胞和/或间充质干细胞组装以代表体内存在的肿瘤。 本发明教导了产生含有类似于体内生长的肿瘤的抗原性质的现成肿瘤疫苗的手段，其不能在现有的二维肿瘤培养装置产生细胞系下复制
-
公开(公告)号：US20190224292A1
公开(公告)日：2019-07-25
申请号：US16250897
申请日：2019-01-17
申请人： BATU BIOLOGICS, INC.
发明人： Samuel C. Wagner , Thomas E. Ichim
摘要： Disclosed are means, methods, and compositions of matter useful for augmentation of a vaccine induced antitumor immune response through immunological targeting of tumor endothelium. In one embodiment a cancer antigen specific vaccine is combined with an endothelial targeting vaccine in a manner to facilitate release of tumor antigens as a result of endothelial destruction. The released tumor antigens serve to amplify immune response induced by the cancer antigen specific vaccine. In one embodiment an endogenous cancer vaccine is utilized as a source of immunization. The endogenous cancer vaccine may be cancer cells induced to die locally such as by means of: hyperthermia, irradiation, oncolytic virus exposure, and embolization.
-
公开(公告)号：US20190167720A1
公开(公告)日：2019-06-06
申请号：US16031850
申请日：2018-07-10
申请人： Batu Biologics Inc.
发明人： Samuel C. Wagner , Thomas Ichim
IPC分类号： A61K35/17 , A61K31/704 , A61K31/407 , A61K31/136 , C12N9/22 , A61K38/14
摘要： Disclosed are methods, protocols, and compositions of matter useful for induction and/or propagation of antitumor immune responses through gene editing of immunocytes. Stimulation of antitumor adaptive immunity is achieved through gene editing of autologous or allogeneic lymphocytes in a manner to derepress neoplasia induced suppression. The method can include targets of gene editing disclosed in the current invention include the E3 ubiquitin ligase Cb1-b, CTLA-4, PD-1, TIM-3, killer inhibitory receptor (KIR) and LAG-3.
-
公开(公告)号：US20180264049A1
公开(公告)日：2018-09-20
申请号：US15924595
申请日：2018-03-19
申请人： Batu Biologics, Inc.
发明人： Samuel C. Wagner , Thomas E. Ichim
摘要： Disclosed are materials, methods, and protocols for inducing a therapeutic response in ocular conditions, such as diabetic retinopathy and wet macular degeneration, by immunizing with placental endothelial cells. In one embodiment, the invention teaches the administration of placental endothelial cells or products thereof, in an immunogenic context to induce antibody and/or cellular immune responses towards ocular neovascularization. The immunogenicity may be endowed by treatment with interferon gamma or agents known to induce upregulation of HLA. In one embodiment, the invention produces antibodies selectively targeting VEGF-associated angiogenesis characterized by a higher degree of vascular permeability as compared to non-malignant angiogenesis. In another embodiment, the invention provides means of inducing antibodies to vasculature associated with aberrant ocular angiogenesis through immunization with endothelial cells grown in conditions resembling tumor endothelial cells.
-
公开(公告)号：US20170216354A1
公开(公告)日：2017-08-03
申请号：US15418149
申请日：2017-01-27
申请人： Batu Biologics, Inc.
IPC分类号： A61K35/15
CPC分类号： A61K35/15 , C12N5/0639
摘要： Disclosed are compositions, methods of use, and pharmaceutical preparations useful for treatment of cancer. In one embodiment dendritic cells (DC) are generated from a patient in need of treatment, matured utilizing a leukocyte lysate, and readministered into the same patient without the use of antigen pulsing. DC from different tissues, different stages of maturation, and different methods of inducing DC maturation are disclosed.
-
公开(公告)号：US20170152506A1
公开(公告)日：2017-06-01
申请号：US15249593
申请日：2016-08-29
申请人： BATU BIOLOGICS, INC.
发明人： SAMUEL C. WAGNER , THOMAS E. ICHIM
CPC分类号： C12N15/102 , C12N15/85 , C12N15/902
摘要： Disclosed are methods, protocols, and compositions of matter useful for generation of lymphocytes with permanently inactivated immunological checkpoint genes, said genes comprising PD-1, CTLA-4, LAG-3, and TIM-3. The generated lymphocytes may be autologous or allogeneic, and are useful in the treatment of neoplastic, viral or bacterial infections.
-
公开(公告)号：US20170128555A9
公开(公告)日：2017-05-11
申请号：US15043422
申请日：2016-02-12
申请人： Batu Biologics, Inc.
发明人： Samuel C. Wagner , Thomas E. Ichim
IPC分类号： A61K39/00
CPC分类号： A61K39/0005 , A61K35/44 , A61K2039/515 , A61K2039/585
摘要： Disclosed is the new, useful, and unexpected finding that immunization to placental endothelial cells stimulated with interferon gamma result in antibodies to the checkpoint inhibitor PD-L1. In one embodiment, the invention teaches the use of ValloVax™ to induce immunological hyperresponsiveness and reduction of costimulatory need for T cell activation. In another embodiment the invention teaches means of selecting placental populations for enhanced expression of PD-L1 in order to augment immunity towards checkpoint inhibitors.
-
-
-
-
-
-
-
-
-
搜索结果
36 条记录 (耗时 0.02 秒)
